A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells

Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) of potential use in patients with breast cancer. Unfortunately, in clinical studies, gefitinib is often ineffective indicating that resistance to EGFR inhibitors may be a common occurrence in cancer of the breast...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Giordano, Courtney R., Mueller, Kelly L., Terlecky, Laura J., Krentz, Kendra A., Bollig-Fischer, Aliccia, Terlecky, Stanley R., Boerner, Julie L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3858180/
https://ncbi.nlm.nih.gov/pubmed/22687878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yexcr.2012.06.001
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller